Allergo Journal International最新文献

{"title":"Position paper on the documentation of biologic therapies for severe asthma","authors":"Ludger Klimek,&nbsp;Roland Buhl,&nbsp;Randolf Brehler,&nbsp;Eckard Hamelmann,&nbsp;Marcus Joest,&nbsp;Kristin aufm Kampe,&nbsp;Stephanie Korn,&nbsp;Sabine Lampert,&nbsp;Norbert Mülleneisen,&nbsp;Christian Taube,&nbsp;Jordis Trischler,&nbsp;Christian Vogelberg,&nbsp;Florian Schmitz,&nbsp; Marek Lommatzsch","doi":"10.1007/s40629-026-00368-w","DOIUrl":"10.1007/s40629-026-00368-w","url":null,"abstract":"<div><h3>Background</h3><p>Biologics are the first-line treatment for patients with severe, inadequately controlled asthma. They can lead to a significant reduction in (or even complete avoidance of) exacerbations, a reduction in the need for systemic glucocorticoids with their many side effects, and a marked improvement in asthma control and lung function in severe asthma. Due to the high annual costs of biologic therapy, there is legitimate interest among health insurances in guideline- and approval-compliant as well as cost-effective use of biologics in severe asthma. On the other hand, there is also legitimate interest among treating physicians in prescribing these biologics without risk of insurer repayment demands.</p><h3>Methodology</h3><p> Using an analysis of the literature and regulatory approvals, the evidence for treatment with currently approved biologics for severe asthma—omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and depemokimab— was documented, and supplemented by the clinical experiences of the authors.</p><h3>Results</h3><p>Based on the guideline recommendations and approvals, recommendations are made for the use of the aforementioned biologics in the German healthcare system. In a joint effort by various professional associations (AeDA, DGP, BdP, GAN, DGAKI, GPP, GPA), documentation forms were created for all biologics approved for severe asthma, which can serve as a basis for documentation. Forms were developed both for the initiation of biologic therapy and for the documentation of biologic treatment responses in severe asthma.</p><h3>Conclusion</h3><p>The new documentation forms concisely summarize all key points related to biologic prescription in severe asthma on a single page, serving both to ensure guideline-compliant and approval-compliant prescription and to avoid drug repayment demands.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"65 - 76"},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00368-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional strategies and alternative protein sources for individuals with oilseed allergies: a narrative review","authors":"Elif Nur Çakar Dietitian MSc (Cont.),&nbsp; Seda Çiftçi","doi":"10.1007/s40629-026-00367-x","DOIUrl":"10.1007/s40629-026-00367-x","url":null,"abstract":"<div><p>Food allergies are a growing global health concern, with oilseed allergies particularly significant due to their association with severe and potentially life-threatening reactions. The prevalence of oilseed allergies is increasing worldwide, affecting children and adults alike. Common allergenic oilseeds include peanuts, walnuts, almonds, cashews, pistachios, sesame, and, in some regions, hazelnuts and sunflower seeds. Although these foods are rich in protein, healthy fats, and micronutrients, they can trigger serious reactions even at trace levels. Symptoms range from mild skin manifestations to anaphylaxis, complicating diagnosis and management. Diagnosis typically involves dietary history, skin prick tests, serum-specific immunoglobulin E analysis, elimination diets, and oral food challenges. Strict avoidance remains the main management strategy, but maintaining adequate protein intake is essential. Alternative sources such as legumes, cereals, microalgae, edible fungi, and precision fermentation products offer nutritionally adequate and lower-allergen options. Advances in processing further improve protein functionality and safety, supporting both individual nutrition and food system sustainability.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"77 - 86"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type I sensitization profiles in patients with spice syndromes","authors":"Benjamin Walz,&nbsp;Vincent Walter,&nbsp;Laura Schmidberger,&nbsp;Manfred Kneilling,&nbsp;Jörg Fischer,&nbsp;Sebastian Volc","doi":"10.1007/s40629-026-00364-0","DOIUrl":"10.1007/s40629-026-00364-0","url":null,"abstract":"<div><h3>Background</h3><p>Allergies to spices have not been adequately researched to date, but they are becoming increasingly important in allergology. The clinical spectrum ranges from mild symptoms to anaphylaxis. Spice allergies can occur as cross-reactions in the form of spice syndromes if type I sensitization to herb pollen is present. The aim of this study was to precisely characterize cross-reactive spice syndromes and their sensitization profiles. Particular attention was paid to the manifestation of mugwort–(celery)–spice syndrome, mugwort–tropical fruit syndrome, and latex–tropical fruit syndrome.</p><h3>Methods</h3><p>We performed a retrospective evaluation of 64 patients who were examined for spice syndromes at the University Dermatology Clinic in Tübingen between 2019 and 2024. Diagnoses and cutaneous and serological evidence of specific IgE antibodies were recorded.</p><h3>Results</h3><p>Patients with mugwort–(celery)–spice syndrome in our cohort were characterized by frequent sensitization to aeroallergens, especially ragweed and mugwort. Serological sensitization to PR10 homologues was common, while sensitization to profilins and to the mugwort major allergen Art v 1 (PR12) was less common. In patients with mugwort–tropical fruit syndrome, sensitization to herbs was particularly common, with all patients testing positive for the mugwort major allergen Art v 1. There was more frequent cutaneously detectable sensitization to labiate plants in mugwort–(celery)–spice syndrome compared to mugwort–tropical fruit syndrome, while sensitization to umbelliferous plants and other spices occurred with similar frequency in both groups. Only one patient had latex–tropical fruit syndrome.</p><h3>Conclusion</h3><p>The results highlight the complex immunological cross-reactivities between pollen and plant allergens and may contribute to a more comprehensive understanding of spice syndromes.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"87 - 97"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00364-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of severe allergic reactions and anaphylaxis with an adrenaline nasal spray","authors":"Regina Treudler,&nbsp;Kirsten Beyer,&nbsp;Katharina Blümchen,&nbsp;Sunhild Gernert,&nbsp;Michael Gerstlauer,&nbsp;Eckard Hamelmann,&nbsp;Thilo Jakob,&nbsp;Ludger Klimek,&nbsp;Oliver Pfaar,&nbsp;Franziska Ruëff,&nbsp;Sabine Schnadt,&nbsp;Marc Schönherr,&nbsp;Sebastian Seurig,&nbsp;Christian Vogelberg,&nbsp;Dorothea Wieczorek,&nbsp;Margitta Worm,&nbsp; Eike Wüstenberg","doi":"10.1007/s40629-026-00363-1","DOIUrl":"10.1007/s40629-026-00363-1","url":null,"abstract":"<div><p>First-line therapy for a severe allergic reaction (anaphylaxis) is the administration of adrenaline, which, in an emergency, can be self-administered intramuscularly (i.m.) via an adrenaline autoinjector (AAI). Despite the known risk of anaphylaxis, AAIs are often not prescribed, not carried, not used, or used with delay in an emergency. Possible reasons for this include logistical issues (e.g., size and portability of the AAI), difficulties in recognizing symptoms that require the use of an AAI, lack of familiarity with the AAI application, and general fear of injections. Recently, an adrenaline nasal spray (ANS) for intranasal application of adrenaline has been authorized and introduced in Germany. Pharmacokinetic studies for ANS development in comparison with the i.m. injection using an AAI or manual injection (syringe and needle) resulted in comparable profiles. The simple use and small size of the ANS, the needle-free design, and the improved storage conditions can help reduce barriers to adrenaline administration for patients and other users. This may lead to an earlier administration of adrenaline in anaphylaxis treatment.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 2","pages":"38 - 44"},"PeriodicalIF":0.0,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00363-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastocytosis and insect venom allergy: a special relationship","authors":"Frank Siebenhaar,&nbsp;Nicole Nojarov,&nbsp;Polina Pyatilova","doi":"10.1007/s40629-025-00361-9","DOIUrl":"10.1007/s40629-025-00361-9","url":null,"abstract":"<div><p>Mastocytosis, a clonal mast cell disorder, is strongly associated with severe insect venom allergy. This review summarizes the pathophysiologic mechanisms linking mastocytosis and Hymenoptera venom anaphylaxis and discusses diagnostic and therapeutic strategies. Patients with mastocytosis are at markedly increased risk for sting-induced anaphylaxis, often presenting with cardiovascular collapse and minimal cutaneous signs. Clonal mast cell expansion, usually driven by <i>KIT</i> D816V, lowers the threshold for mediator release. Baseline tryptase is typically elevated, but normal levels do not exclude disease, as occult mastocytosis may still be present. Hereditary alpha-tryptasemia (HαT), a genetic trait causing elevated tryptase, further increases risk and may coexist with mastocytosis. The diagnostic work-up in patients with venom allergy should include serum tryptase, venom-specific IgE (with component-resolved diagnostics), and <i>KIT</i> mutation analysis in patients with severe reactions. Bone marrow biopsy is indicated if suspicion remains high. Detection of <i>KIT</i> D816V is an independent predictor of severe sting reactions. Venom immunotherapy (VIT) is highly effective and lifesaving but associated with more frequent systemic reactions in mastocytosis (&gt; 20%). Omalizumab may improve VIT safety in high-risk cases. Given the high relapse risk, lifelong VIT is recommended, along with epinephrine autoinjectors and rigorous emergency preparedness. Personalized management including risk stratification by <i>KIT</i> and HαT status, optimized VIT protocols, adjunctive therapy, and patient education is essential. Mastocytosis and venom allergy form a unique clinical constellation requiring proactive diagnosis and individualized long-term management to prevent fatal reactions.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 1","pages":"1 - 7"},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00361-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Non-purified” Hymenoptera venom extracts—from protein to preferred product","authors":"Matthias F. Kramer MD","doi":"10.1007/s40629-025-00362-8","DOIUrl":"10.1007/s40629-025-00362-8","url":null,"abstract":"<div><p>Hymenoptera venom extracts for allergen-specific immunotherapy (AIT) are marketed with the attributes “purified” or “highly purified” or “non-purified.” However, all manufacturing processes include purification steps and are subject to the same requirements of the European Pharmacopoeia. European and national guidelines confirm that “purified” and “non-purified” Hymenoptera venom AIT (VIT) do not differ in their effectiveness and frequency of systemic adverse events (AE). Differences in preserving natural venom composition appear more relevant. Hymenoptera venom AIT is considered the success model for AIT. Protection rates of close to 100% can be achieved for both bees and wasps. However, with several years of administration of aluminum, depot VIT is also considered a role model for iatrogenic aluminum exposure through long-term subcutaneous immunotherapy (SCIT). Its relevant iatrogenic contribution to the accumulation of aluminum in the body is now widely recognized. Considering patient preferences improves adherence, among others. “Our own” surveys conducted by the author, comparing product characteristics of SCIT preparations, indicate that patients prefer products without aluminum.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 1","pages":"22 - 27"},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00362-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the serological bee/vespula venom-specific IgE ratio supplemented by component-resolved diagnostics a reliable alternative to skin testing for hymenoptera venom allergy?","authors":"Jörg Fischer,&nbsp;Ralf Wenninger,&nbsp;Lena Löffelad,&nbsp;Sebastian Volc","doi":"10.1007/s40629-025-00359-3","DOIUrl":"10.1007/s40629-025-00359-3","url":null,"abstract":"<div><h3>Background</h3><p>A reliable diagnosis of hymenoptera venom allergy is based on medical history, skin tests, and serological immunoglobulin E (IgE) determination. Over the past 10 years, component-resolved diagnostics (CRD) have gained in importance, and new strategies for interpreting serological double sensitization have been introduced with the bee/vespula venom-specific IgE ratio.</p><h3>Objectives</h3><p>The aim was to examine whether the bee/vespula venom-specific IgE ratio supplemented by CRD can be a reliable alternative to skin testing.</p><h3>Methods</h3><p>In a student project, the guideline algorithm for serological diagnostics was supplemented with the sIgE ratio (≥ 5:1) and tested in a simulation using anonymized data from a retrospective study (Fischer et al.). A partial data set of 375 cases with complete CRD and documented prick and intradermal test results was selected for the simulation. The performance of the algorithm was evaluated by a post hoc comparison of the algorithmic therapy recommendations with the allergen immunotherapies (AIT) actually implemented in the clinic.</p><h3>Results</h3><p>The simulation yielded 48.5% monosensitizations and 49.9% double sensitizations. In 56.3% of the double sensitizations, the ratio ≥ 5:1 indicated a dominant sensitization, which was classified as a mono-allergy. The therapies suggested by the algorithm corresponded to the clinically implemented AIT in 91% of cases; overall, the correspondence was 89.7%. While the algorithm predicted double AIT in 10% of cases, this was only clinically implemented in 2.7% of cases, with anamnestic details on sting circumstances and diagnostic certainty influencing the decision.</p><h3>Conclusion</h3><p>Standardized serological diagnostics with bee/vespula venom-specific IgE ratio and CRD provide high diagnostic precision and comprehensively demonstrate the progress made over the last 10 years. Skin tests remain a medically useful and valuable part of diagnostics, especially in cases of double sensitization.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 1","pages":"15 - 21"},"PeriodicalIF":0.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00359-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antihistamine-induced urticaria","authors":"Celine Galleani MD,&nbsp;Alicia Enríquez-Matas MD, PhD,&nbsp;Ruth Mielgo-Ballesteros MD,&nbsp;Inmaculada Piorno MD,&nbsp;Maria José Peñalver MD,&nbsp;Beatriz Cabanillas PhD,&nbsp;Jesús Fernández Crespo MD, PhD","doi":"10.1007/s40629-025-00360-w","DOIUrl":"10.1007/s40629-025-00360-w","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"98 - 99"},"PeriodicalIF":0.0,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerance induction by insect venom immunotherapy under B-cell depletion with an anti-CD20 antibody","authors":"Iris Hennighausen,&nbsp;Sophie Hermann,&nbsp;Christian Möbs,&nbsp;Wolfgang Pfützner","doi":"10.1007/s40629-025-00353-9","DOIUrl":"10.1007/s40629-025-00353-9","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 8","pages":"294 - 296"},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00353-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145698710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of hereditary angioedema: advances and gaps in care","authors":"Robin Lochbaum,&nbsp;Petra Staubach-Renz","doi":"10.1007/s40629-025-00358-4","DOIUrl":"10.1007/s40629-025-00358-4","url":null,"abstract":"<div><p>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and repeated swelling in various parts of the body. In the respiratory tract, these attacks are potentially life-threatening. Since neither the timing of the attacks nor their location or severity can be predicted, the quality of life of affected patients is often severely impaired. Important therapeutic advances have been made in recent years and decades. For example, the possibility of self-administering medication has enabled those affected to respond quickly to HAE attacks. Another milestone was the establishment of long-term prophylaxis, which can guarantee freedom from attacks over a long period of time for some patients. Despite these advances, all affected individuals are required to always carry medication for acute treatment. The patient population is very heterogeneous and always requires individualized therapy planning in each case. It is important to adapt the management options to the respective life situations, which can be done at any time. In practice, the implementation of the therapy concept can be associated with various challenges. These will be discussed in this publication based on available data and our own experience to highlight the problems faced by patients and practitioners and how these barriers can potentially be removed or overcome.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 2","pages":"29 - 37"},"PeriodicalIF":0.0,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00358-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}